QuidelOrtho Corporation

QuidelOrtho Corporation is a healthcare company that provides diagnostic testing solutions. Its operations are organized into four business units: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. The Labs unit offers clinical chemistry and immunoassay laboratory instruments and tests that measure chemicals and proteins in bodily fluids to evaluate health and manage patients. The Transfusion Medicine unit provides immunohematology instruments for blood typing and donor screening tests for infectious diseases. The Point of Care unit delivers rapid diagnostic results across various point-of-care settings. The Molecular Diagnostics unit offers polymerase chain reaction thermocyclers, amplification systems, and sample-to-result molecular instruments for syndromic infectious disease diagnostics.

QuidelOrtho Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol QDEL. Its shares are traded in United States Dollars (USD), as the company is based in the United States and its stock is listed on a U.S. exchange.

QuidelOrtho Corporation operates in the Healthcare sector and is specifically classified under the Medical Devices industry. This means the company develops and manufactures medical devices and diagnostic equipment used by healthcare professionals to detect and monitor diseases, rather than providing direct patient care or developing pharmaceuticals.

QuidelOrtho Corporation is headquartered in the United States and serves the U.S. market as its primary region. The company sells its diagnostic products directly to end users through a direct sales force and also through a network of distributors. Its customers include physician offices, hospitals, clinical laboratories, and reference laboratories, indicating a focus on professional healthcare settings.

QuidelOrtho Corporation generates revenue by selling diagnostic testing instruments and consumables across its four business units. The Labs unit provides clinical chemistry and immunoassay instruments and tests. The Transfusion Medicine unit sells blood typing and donor screening equipment. The Point of Care unit offers rapid diagnostic devices for various settings. The Molecular Diagnostics unit provides PCR thermocyclers and molecular tests. The company sells directly to end users via a direct sales force and through distributors, targeting physician offices, hospitals, clinical labs, and reference labs. Recurring revenue from test consumables and service contracts likely complements initial instrument sales.